• 2025-03-26 06:09:21

While the Philippines' ambitious Universal Health Care Act and substantial government investment are creating a rapidly expanding market for medical devices, the nation's overwhelming reliance on imports starkly contrasts with its limited domestic manufacturing capabilities. This situation, however, creates an opening for overseas manufacturers to provide the needed medical devices and take advantage of the increasing market.

• 2025-01-22 06:13:50

Administrative Order No. 2024-0016 sets a new schedule of fees and charges by the Food and Drug Administration (FDA) of the Philippines for all regulated products, including medical devices, drugs, food, and cosmetics. The updated fees aim to simplify compliance for manufacturers and distributors while keeping pace with the growing demands of the healthcare industry. This change ensures more efficient processes for licensing, product registration, and market access.

• 2024-05-07 09:12:46

The Food and Drug Administration (FDA) has recently issued Circular No. 2024-003, which extends the regulatory flexibility and application of CMDN for medical devices under Class B, C, and D that are not listed as registrable medical devices in FDA Circular No. 2020-001-A.

• 2024-04-03 09:16:23

The Philippine Food and Drug Administration (PFDA) released an advisory on March 06, 2024 announcing that COVID-19 Medicines and Devices will no longer be VAT-exempt, effective 01 January 2024. This is due to the expiration of the VAT exemption provision in the CREATE Act.

• 2023-09-27 06:13:09

The Philippine Food and Drug Administration (PFDA) released the 2023 edition of the citizen charter, including updates related to the Center for Device, Radiation Health, and Research (CDRRHR).

• 2023-09-27 05:49:24

The FDA has introduced the Customer Relation Management Information System (CRMIS), a digital platform that enables stakeholders and the public to submit inquiries and follow-ups. The system began on August 28, 2023, and will run until November 30, 2023, as part of the FDA's commitment to improving public health services and IT infrastructure.

• 2023-04-24 09:37:45

On March 31, 2023, PFDA has once again extended the application period for one more year for medical device products that were previously considered non-registrable, which currently fall under AMDD risk class B-D. PFDA cites the risk of disrupting the supply chain that may negatively impact the quality of the healthcare system in the country.

• 2023-03-27 08:52:43

PFDA presented a draft of the updated guidelines on obtaining a special permit for restricted use of unregistered drug and medical device products. In addition to previous patient conditions laid out by previous regulations, this new guidance widens the product scope to vaccines and the diseases to include those that may result in the patient's permanent disability.

• 2022-11-29 01:55:34

PFDA issued FDA Circular No. 2022-008 that provides a guideline on the abridged process for registration of medical devices among ASEAN member countries.

• 2022-11-29 01:39:35

The Food and Drug Administration (FDA) announced the effectivity extension of FDA Circular No. 2021-025, a guideline for application of authorization due to extended state of public health emergency.